Patients’ Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment

• DOI: 10.1007/s40271-016-0172-1
• Publication Date: 2016-05-11T04:50:17Z
• Authors: James Buchanan; Sarah Wordsworth; Anna Schuh
• Keywords: Genomic information

Genomic information could help to reduce the morbidity effects of inappropriate treatment decisions in many disease areas, particular cancer. However, evidence benefits that patients derive from genomic testing is limited. This study evaluated patient preferences for context chronic lymphocytic leukaemia (CLL). We used a discrete choice experiment (DCE) survey assess CLL UK testing. The presented with 16 questions which they had choose between two possible test scenarios. Tests these scenarios were specified terms six attributes, including effectiveness, reliability and time receive results. 219 completed (response rate 20 %). Both clinical process-related attributes valued by respondents. Patients willing pay £24 1 % increase chemotherapy non-responders identified, £27 results day. also wait an extra 29 days if additional one-third be would tolerate being wrong 8 this information. value provided tests, prefer combinations characteristics more closely reflect future practice than current genetic practice. Commissioners will need carefully consider how operationalised are realised.